Regencell Bioscience Holdings Limited
RGC
$12.80
$0.241.91%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.26% | -11.33% | -1.94% | -4.02% | -5.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.50% | -27.59% | -30.21% | -23.83% | -17.64% |
| Operating Income | 24.50% | 27.59% | 30.21% | 23.83% | 17.64% |
| Income Before Tax | 28.03% | 30.17% | 31.97% | 25.94% | 20.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.03% | 30.17% | 31.97% | 25.94% | 20.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -67.89% | -21.15% | 31.72% | 30.29% | 28.67% |
| Net Income | 26.73% | 30.42% | 33.49% | 27.16% | 21.15% |
| EBIT | 24.50% | 27.59% | 30.21% | 23.83% | 17.64% |
| EBITDA | 27.06% | 30.35% | 32.61% | 25.92% | 19.48% |
| EPS Basic | 26.67% | 30.30% | 33.33% | 27.52% | 22.08% |
| Normalized Basic EPS | 5.56% | 16.67% | 25.00% | 25.00% | 25.00% |
| EPS Diluted | 26.67% | 30.30% | 33.33% | 27.52% | 22.08% |
| Normalized Diluted EPS | 5.56% | 16.67% | 25.00% | 25.00% | 25.00% |
| Average Basic Shares Outstanding | 0.00% | -0.02% | -0.03% | 0.79% | 1.62% |
| Average Diluted Shares Outstanding | 0.00% | -0.02% | -0.03% | 0.79% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |